Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis

Completed

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT02008266
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This non-interventional, descriptive, cross-sectional and multicenter study will examine the treatment of rheumatoid arthritis progressing for less than two years in the Algerian population. Current drug therapy as well as disease status and patient function will be assessed.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Study First Submitted: 2013-11-27
• Status Verified: 2013-12
• Study First Submitted QC: 2013-12-06
• Last Update Submitted: 2013-12-06
• Study First Posted: 2013-12-11
• Last Update Posted: 2013-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 532

Inclusion Criteria

• Rheumatoid arthritis progressing for < 2 years.

Read More

Exclusion Criteria

• Rheumatoid arthritis progressing for < 3 months.
• Rheumatoid arthritis onset at < 18 years of age.
• Participation in another clinical study.
• Rheumatoid arthritis related connective tissue disorder.
• Any neuropsychological disorders.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe medications used in the treatment of rheumatoid arthritis with < 2 years' progression.	Single observational visit [Day 1]

Secondary Outcome Measures

Name	Time	Method
Measure disease activity using DAS 28 assessment.	Single observational visit [Day 1]
Assess joint damage using the modified SHARP method.	Single observational visit [Day 1]
Assess functional status of patients using the Health Assessment Questionnaire (HAQ).	Single observational visit [Day 1]